The HMR C-terminus is required for HMR physiological function in <i>D</i>. <i>melanogaster</i>. by Andrea Lukacs (3752956)

Estimated regression effects. by Kimmo Sorjonen (495847)

1866 and DANA effects on MCD-induced changes in white adipose tissue. by Darrell Pilling (68014)

ERF1 directly binds to <i>ASA1</i> promoter region <i>in vitro</i> and <i>in vivo</i>. by Jie-Li Mao (844282)

FLIM FRET efficiency of: (A) αA-crystallin (B) WT αB-crystallin, their deamidated and domain mutants. by Ekta Tiwary (836674)

“…<p>FRET efficiency was calculated from the decrease in life-lime (presented in Fig 8) in 5 to 6 cells. …”

Effect of rapamycin (1 ng/ml) and anti-EGFR antibody (5 µg/ml) on reactivity with monoclonal HMB45 in human TSC2^−/−ASM cells. by Elena Lesma (269724)

“…A: Incubation at cell plating time with anti-EGFR for 48 hours decreases markedly the number of cells reacting to HMB45 while the number of negative cells is strongly increased. …”

Radioligand binding and intracellular trafficking properties of MC1R-TUBB3 isoforms. by Cecilia Herraiz (836697)

N-terminal huntingtin fragments in control temporal cortex tissue from an individual subject. by Menno H. Schut (4060249)

3D model of the compressor. by Jingya Dong (19959282)

Depleting extracellular ATP reverts the mesenchymal phenotype of ovarian carcinoma cell lines. by José David Nuñez-Ríos (18823719)

qRT-PCR analysis of the relative expression levels of TGF-β1, BMP-4 and Smads in embryonic bladders from E12.5 to neonatal day0. by Syed S. Islam (404861)

“…Smad4 showed the highest expression pattern from E12.5 to E16.5 and decreased in E18.5 and neonatal day0 <i>(Mann-Whitney test, p<0.005)</i> and <b>D</b>) Inhibitory Smads. …”

Data_Sheet_1_Ribozyme-Mediated Downregulation Uncovers DNA Integrity Scanning Protein A (DisA) as a Solventogenesis Determinant in Clostridium beijerinckii.pdf by Victor Chinomso Ujor (10939044)

“…Unexpectedly, C. beijerinckii_M1GS^CcpA–Sc produced 50% more solvent than C. beijerinckii_pMTL500E grown on glucose + arabinose. …”

Conceptual diagram of O₂-gradient chamber. by Noelle M. Lucey (7847078)

DataSheet_2_Immunotherapeutic Effects of Different Doses of Mycobacterium tuberculosis ag85a/b DNA Vaccine Delivered by Electroporation.pdf by Yan Liang (139654)

“…</p>Methods<p>Ninety-six female BALB/c mice were challenged with 2×10⁴ colony-forming units (CFUs) of MTB H₃₇Rv through tail vein injection, then was treated with 10μg, 50μg, 100μg, and 200μg of Mycobacterium tuberculosis (MTB) ag85a/b chimeric DNA vaccine delivered by intramuscular injection (IM) and electroporation (EP), respectively. …”

DataSheet_1_Immunotherapeutic Effects of Different Doses of Mycobacterium tuberculosis ag85a/b DNA Vaccine Delivered by Electroporation.pdf by Yan Liang (139654)

“…</p>Methods<p>Ninety-six female BALB/c mice were challenged with 2×10⁴ colony-forming units (CFUs) of MTB H₃₇Rv through tail vein injection, then was treated with 10μg, 50μg, 100μg, and 200μg of Mycobacterium tuberculosis (MTB) ag85a/b chimeric DNA vaccine delivered by intramuscular injection (IM) and electroporation (EP), respectively. …”

DCP-LA treatment of SN56 cells diverts APP into early endosome compartments. by Joshua H. K. Tam (836784)

Mutational landscape of TCL cell lines. by Rufino Mondejar (4025846)

Baseline characteristics of the study sample^βμ. by Osama Mohamed Ibrahim (12006954)

“…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”

The flow diagram of the study (CONSORT, 2010). by Osama Mohamed Ibrahim (12006954)

“…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”

Table_1_Incidence and risk factors of severe acute high-altitude illness in healthy adults first entering the northern Tibetan Plateau of over 5,000 m.DOC by Chun Gao (622218)

“…</p>Conclusion<p>Living at lower altitudes and having a decreased lymphocyte level were the risk factors of severe AHAI in healthy adults first entering the plateau of over 5,000 m.…”